不可切除Ⅲ期非小细胞肺癌同步放化疗采用调强放疗后续度伐利尤单抗的疗效特征:一项多中心回顾性队列研究
该多中心回顾性队列研究纳入日本7家中心2018年5月至2019年12月接受同步放化疗(IMRT)的107例Ⅲ期非小细胞肺癌患者,其中87例序贯接受度伐利尤单抗。中位随访29.7个月,中位无进展生存期(PFS)为20.7个月。多因素分析显示同步放化疗反应良好、放疗剂量≥62 Gy和ⅢA期与PFS延长相关(均P=0.04);度伐利尤单抗治疗时长≤11.7个月、较低最高级别免疫相关不良事件、FEV1<2805 mL和放疗剂量<62 Gy为死亡风险因素。
要点
- 107例Ⅲ期NSCLC患者接受IMRT同步放化疗,87例序贯度伐利尤单抗,中位PFS为20.7个月。
- 同步放化疗反应良好、放疗剂量≥62 Gy和ⅢA期与PFS延长相关(均P=0.04)。
- 度伐利尤单抗治疗时长≤11.7个月与死亡风险相关(P=0.01)。
核心结论
- 在接受IMRT同步放化疗的NSCLC患者中,较长的PFS与对同步放化疗更好的反应、ⅢA期NSCLC和增加的放疗剂量相关;度伐利尤单抗巩固治疗时长也对接受IMRT同步放化疗患者的生存起重要作用。
研究设计与样本
- 多中心回顾性队列研究,回顾日本7家中心2018年5月至2019年12月接受IMRT同步放化疗的Ⅲ期非小细胞肺癌患者临床记录,主要终点为无进展生存期(PFS)。
主要发现
- 共纳入107例患者,其中87例序贯接受度伐利尤单抗;自同步放化疗开始中位随访29.7个月,同步放化疗结束时中位PFS为20.7个月。
- 87例中58例出现疾病复发,其中36例(62.1%)为远处转移。
- 多因素Cox回归分析显示,对同步放化疗反应良好、放疗剂量≥62 Gy和ⅢA期NSCLC与PFS延长相关(均P=0.04)。
- 界标分析的多因素logistic回归显示,死亡风险因素为度伐利尤单抗治疗时长≤11.7个月、较低的免疫相关不良事件最高级别、FEV1<2805 mL和放疗剂量<62 Gy(P分别为0.01、0.01、0.03和0.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intensity-modulated radiotherapy (IMRT) is currently used more commonly than 3-dimensional conformal radiation for definitive thoracic radiation. We examined the efficacy profiles of concurrent chemoradiotherapy (CCRT) with IMRT after durvalumab became clinically available. METHODS: We reviewed the clinical records of patients with stage III non-small cell lung cancer (NSCLC) treated with CCRT and IMRT at seven centers in Japan and investigated relapse and survival from May 2018 to December 2019. The primary endpoint of this report was progression-free survival (PFS). RESULTS: Among 107 patients enrolled in the study, 87 were sequentially administered durvalumab. From CCRT commencement, patients were followed up for a median period of 29.7 months. The median PFS at the end of the CCRT was 20.7 months. Among the 87 patients, 58 experienced disease relapses, of whom 36 (62.1 %) had distant metastases. Multivariate Cox regression analysis revealed that a favorable response to CCRT, a radiation dose ≥ 62 Gy, and stage IIIA NSCLC were associated with prolonged PFS (all P = 0.04). Multivariate logistic regression by landmark analysis revealed that mortality risk factors were durvalumab treatment duration ≤ 11.7 months, a lower maximum grade of immune-related adverse events, FEV1 < 2805 mL, and radiation dose < 62 Gy (P = 0.01, 0.01, 0.03, and 0.04, respectively). CONCLUSIONS: In patients with NSCLC receiving CCRT using IMRT, long PFS was associated with a better response to CCRT, stage IIIA NSCLC, and an increased radiation dose. The duration of durvalumab consolidation also played an essential role in the survival of patients receiving CCRT with IMRT. (250 words).
引用
- Takeda Y, Kusaba Y, Tsukita Y, et al. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study. Clin Transl Radiat Oncol. 2022. PMID: 36065360. doi:10.1016/j.ctro.2022.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。